Lunai Bioworks Inc. (RENB) Stock Analysis & Investment Frameworks
Lunai Bioworks Inc. (RENB) stock analysis on Invetso. Review Lunai Bioworks Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Lunai Bioworks Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Lunai Bioworks Inc. Key Financial Metrics
- Market Cap: $32.92M
- Revenue: $N/A
- ROE: 157.26%
- ROIC: 113.16%
- Dividend Yield: N/A
About Lunai Bioworks Inc.
Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline features several candidates, specifically ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. Founded on January 18, 2011, by Rene Sindlev and Serhat Gumrukcu, Lunai Bioworks maintains its corporate base in Los Angeles, California.